LUND, Sweden, March 2, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company
developing antibody-based pharmaceuticals for tumor-directed
immunotherapy, announced today that the Swedish version of the
Annual Report 2019 is available on the company website
www.alligatorbioscience.com. An English version will follow
shortly.
The information was submitted for publication, through the
agency of the contact person set out above, at 10:30 a.m. CET on 2 March
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes six lead clinical and
preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015,
ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics
Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai
Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-s-annual-report-2019-published,c3050289
The following files are available for download:
|
https://mb.cision.com/Main/12681/3050289/1204074.pdf
|
Alligator
Bioscience's Annual Report 2019
|
|
https://news.cision.com/alligator-bioscience/i/alligator-annual-report-cover-thumbnail-2019,c2757240
|
Alligator Annual
report cover thumbnail 2019
|
|
https://mb.cision.com/Public/12681/3050289/ab6550bb17cad7df.pdf
|
200302 Annual Report
2019 PR
|